New data underscores aprocitentan’s potential in managing hypertension in patients with CKD

Switzerland’s Idorsia (SIX: IDIA) announced the publication of a new analysis from the landmark Phase III PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”. The analysis examined the efficacy and safety of aprocitentan (trade names Tryvio and Jeraygo) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk.

The study showed that, at Week 4, aprocitentan 12.5mg and 25mg reduced office systolic BP by –13.5 mm Hg and–16.6 mm Hg, respectively, versus –4.4 mm Hg with placebo – with reductions sustained with aprocitentan 25mg through Week 36 (-16.4 mm Hg)

Nighttime ambulatory systolic BP – a strong predictor of cardiovascular and renal outcomes and often poorly controlled in CKD – was reduced by –9.6 mm Hg and –13.8 mm Hg, respectively, versus –2.5 mm Hg with placebo.